医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Notification of a New Drug Application for HP-3070 (Transdermal Patch for the Treatment of Schizophrenia) in the U.S.

2018年12月17日 PM11:00
このエントリーをはてなブックマークに追加


 

MIAMI

Hisamitsu Pharmaceutical Co., Ltd. (Headquarters: Tosu City, Saga Prefecture, President and Chief Executive Officer (CEO): Hirotaka Nakatomi, hereinafter “Hisamitsu Pharmaceutical”), in conjunction with its U.S. subsidiary, Noven Pharmaceuticals, Inc., announces that a New Drug Application has been submitted to the U.S. Food and Drug Administration (FDA) seeking approval of HP-3070 (asenapine) transdermal system for the treatment of schizophrenia (Development code: HP-3070, generic name: asenapine, hereinafter referred to as “the investigational product”).

The investigational product is a systemic transdermal formulation developed using Hisamitsu Pharmaceutical’s Transdermal Drug Delivery System (TDDS) technology. Hisamitsu Pharmaceutical expects the investigational product to be a new option in the treatment of schizophrenia. The development of the investigational product represents Hisamitsu Pharmaceutical’s commitment to improving the lives of the community of patients who live with schizophrenia.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181217005053/en/

CONTACT

Stephanie Lamenta
Noven Pharmaceuticals
305-253-1916

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Takeda to Divest TachoSil® to Corza Health for €350 Million
  • 新たな研究:ハンドドライヤーによる手の乾燥はペーパータオルと同じくらい衛生的
  • Body Fit Training PTY LTD Sues to Invalidate F45 Training PTY LTD’s U.S. Patents
  • Singapore and Apple Partner on National Health Initiative Using Apple Watch
  • 最新研究:干手机与用纸巾擦干双手一样卫生